Thank you for your continued support and commitment to optimizing hemodynamic management and reducing healthcare costs. ImaCor remains dedicated to ensuring the success of your Program for Advanced Hemodynamic Management with hTEE. We would like to provide you with some updates and highlights since our last communication on transforming our business.
We have reached out to our customers and the response has been overwhelmingly positive. Customer sites like yours continue to experience important clinical and economic benefits, as hTEE programs see positive changed patient management 66% of the time.1 Additionally, since our last communication Columbia University Medical Center’s “The Impact of Miniaturized Hemodynamic Transesophageal Echocardiography (hTEE) on Decision-Making in Hemodynamically Unstable Patients in a Cardiothoracic Intensive Care Unit” by M. Hlaing et. al. was presented at the International Society for Heart and Lung Transplantation annual meeting in Nice, France. The authors concluded that hTEE impacted management decisions in 76.6% of examinations. Subsequently, “Feasibility and Influence of hTEE Monitoring on Postoperative Management In Cardiac Surgery Patients” by S.Treskatsch et. al. at Charité University Hospital was published in the International Journal of Cardiovascular Imaging. The authors findings, including the early identification of five unexpected right heart failures and one pericardial tamponade, led to a change of current therapy in 89% of patients.
We continue to assist multiple sites in implementing and expanding their hTEE programs. Several hospitals are launching new programs, including at the Allegheny General Hospital’s SICU in Pittsburgh, Pennsylvania and the Joseph M. Still Burn Center at Doctors Hospital in Augusta, Georgia.
We encourage you to continue providing feedback and to contact us directly if you need our assistance. ImaCor is deeply committed to improving patient outcomes and saving your hospital money. Again, thank you for your business, and we wish you continued success.
 Vieillard-Baron A et. al. A pilot study on safety and clinical utility of a single-use 72-hour indwelling transesophageal echocardiography probe. Intensive Care Med. 2013 Apr;39(4):629-35.